[{"id":"07256400-e75c-40da-9575-fc4a25929b87","acronym":"","url":"https://clinicaltrials.gov/study/NCT03284723","created_at":"2021-01-18T16:13:39.524Z","updated_at":"2024-07-02T16:36:15.120Z","phase":"Phase 1","brief_title":"PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors","source_id_and_acronym":"NCT03284723","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • PF-06804103"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 11/01/2017","start_date":" 11/01/2017","primary_txt":" Primary completion: 08/31/2021","primary_completion_date":" 08/31/2021","study_txt":" Completion: 08/31/2021","study_completion_date":" 08/31/2021","last_update_posted":"2022-03-18"}]